Skip to main content
. 2024 Apr 25;6(8):101102. doi: 10.1016/j.jhepr.2024.101102

Table 2.

Comparison of clinical characteristics between pediatric DILI cases with mild and moderate/severe manifestations.

Characters Total (N = 291) ALT ≥5x ULN or ALP ≥4x ULN and TBIL <2x ULN (Mild, n = 206) ALT ≥5x ULN or ALP ≥4x ULN and TBIL ≥2x ULN and life-threatening DILI (≥Moderate, n = 85) p value
Sex, n (%)
 Boys 171 (60.2) 124 (61.7) 47 (56.6) 0.428
 Girls 113 (39.8) 77 (38.3) 36 (43.4)
Age (year), median (IQR)
 Toddlers (≥30 days and <6 years old) 86 (29.6) 75 (36.4) 11 (12.9) <0.0001
 School-aged children (≥6 and <12 years old) 76 (26.1) 57 (27.7) 19 (22.4)
 Adolescents (≥12 and <18 years) 129 (44.3) 74 (35.9) 55 (64.7)
BMI (kg/m2), median (IQR) 19.1 (16.9, 20.8), n = 129 19.0 (17.2, 20.9), n = 73 19.2 (16.7, 20.8), n = 56 0.640
Duration of using implicated agent (days), median (IQR) 9 (5, 31), n = 151 9 (4, 21), n = 100 11 (7, 50), n = 51 0.019
Latency (days), median (IQR) 17 (8, 53), n = 158 13 (7, 37), n = 101 26 (15, 67), n = 57 0.0005
Hospitalization (days), median (IQR) 14 (7, 22), n = 291 12 (5, 19), n = 206 18 (12, 28), n = 85 <0.0001
Pattern of liver injury, n (%)
 Hepatocellular injury (R ≥5) 158 (620.0) 103 (58.9) 55 (68.8) 0.209
 Cholestatic injury (R ≤ 2) 35 (13.7) 28 (160.0) 7 (8.7)
 Mixed injury (2<R <5) 62 (24.3) 44 (25.1) 18 (22.5)

ALP, alkaline phosphatase; ALT, alanine aminotransferase; DILI, drug-induced liver injury; TBIL, total bilirubin; ULN, the upper limit of normal.

Data are presented as the median (IQR) or n (%), n, where n is the actual number with available data. Pearson chi-square test for categorical variables, Student’s t test for variance, or Wilcoxon rank-sum for continuous variables. Values in bold denote statistical significance.